TXMD — TherapeuticsMD Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $2.11
- 30-Day Move
- +14.7%
- Market Cap
- $27M
- Shares Outstanding
- 11,570,000
- P/E Ratio
- 87.77
- P/B Ratio
- 0.36
TherapeuticsMD Inc
A read-only Alphactor snapshot forTherapeuticsMD Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-22
Topline snapshot
Latest Close
$2.11
30-Day Move
+14.7%
Market Cap
$27M
Shares Outstanding
11,570,000
P/E Ratio
87.77
P/B Ratio
0.36
$2.11
+14.7%last 90 delayed daily bars
90D High
$2.95
90D Low
$1.58
Avg Volume
63,906
Gross margin is running at 100.0%, which gives a quick read on operating quality before you open the full model.
Net margin is 10.8%, useful for comparing TXMD against peers in Pharmaceuticals.
TXMD is up 14.7% over the last 30 trading days shown on this page.
Latest operating income is $-1M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$1.53
Rule of 40
152.8%
Latest Close
$2.11
30-Day Move
+14.7%
Market Cap
$27M
Shares Outstanding
11,570,000
P/E Ratio
87.77
P/B Ratio
0.36
ROE
-8.0%
ROA
-5.6%
Gross Margin
100.0%
Operating Margin
-98.3%
Net Margin
10.8%
Debt / Equity
0
Current Ratio
2.37
Latest Revenue
$893,000
Revenue
$893,000
Gross Profit
--
Operating Income
$-1M
Net Income
$-619,000
Gross Margin
10000.0%
Net Margin
1080.0%
Current Ratio
2.37
Debt / Equity
0.00
Fair Value
$1.53
Upside / Downside
-27.5%
Signal
Overvalued
Implied Growth
-0.3%
DCF
$1.63
EV/Rev
$1.43
Growth Assumption
-10.0%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$2M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Altman Z
-33.91
Distress
Piotroski
6
Moderate (4-6)
Cash Conversion
-4.31x
Rule of 40
152.8%
Elite
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $70M | $11M | $112M | $9M |
| 2023-12-31 | $1M | $-9M | $-10M | $-23M |
| 2024-12-31 | $2M | $-5M | $-2M | $1M |
| 2025-12-31 | $3M | $-4M | $-569,000 | $2M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 244,317 | 0.02% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 83,971 | 0.01% | 2025-12-31 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 67,220 | 0.01% | 2026-02-28 |
| Bridgeway Funds, Inc.-Ultra-Small Company Market Fund | 17,000 | 0.00% | 2025-12-31 |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 15,320 | 0.00% | 2026-02-28 |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 14,835 | 0.00% | 2026-02-28 |
| Gabelli Investor Funds Inc-The Gabelli ABC Fund | 4,000 | 0.00% | 2025-12-31 |
| Gabelli 787 Fund, Inc.-Enterprise Mergers and Acquisitions Fund | 1,000 | 0.00% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Vanguard Group
Filed 2026-01-29
$647,201
+5.4%
BlackRock
Filed 2024-05-10
$310,934
--
Geode Capital Management
Filed 2026-02-09
$172,984
-2.7%
Renaissance Technologies
Filed 2026-02-12
$157,295
+171.8%
Citadel Advisors
Filed 2026-02-17
$46,031
--
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.